tirzepatide safety concerns A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection Frontiers | Efficacy and safety

They differ by: receptor profile approval status trial design tolerability and how much real-world evidence exists today That is why the most honest ranking is not 1st, 2nd, 3rd. It is: semaglutide is the proven single-agonist benchmark tirzepatide is the current approved leader retatrutide is the Phase 3 investigational drug most likely to reshape the market if the remaining data hold Sources New England Journal of Medicine / PubMed: STEP 1 semaglutide trial FDA: Wegovy cardiovascular-risk indication and current indication summary FDA: Zepbound approval for chronic weight management Eli Lilly: SURMOUNT-5 complete results Eli Lilly: TRIUMPH-4 Phase 3 retatrutide results Eli Lilly: retatrutide Phase 3 diabetes results and dysesthesia signal Lilly FAQ: what to know about retatrutide

Gradually increase fiber intake with fruits, vegetables, and whole grains, rather than significantly boosting fiber all at once (something that can lead to bloating and gas)

(4) ongoing telehealth follow-up supports dose titration and side-effect management

Get the temperature right, and your medication stays effective through the full beyond use date

Always consult your doctor or pharmacist before making changes to your medication schedule.

It's marketed as Zepbound for weight management and Mounjaro for type 2 diabetes